Welcome to our dedicated page for Pro-Dex Colo SEC filings (Ticker: PDEX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pro-Dex, Inc. (NASDAQ: PDEX) SEC filings page provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Pro-Dex operates in the surgical and medical instrument manufacturing industry, focusing on autoclavable, battery-powered, and electric multi-function surgical drivers and shavers for orthopedic, thoracic, and maxocranial facial markets, and its filings give detailed insight into how this business is structured and managed.
Through this page, readers can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which include discussions of net sales, gross profit, operating expenses, operating income, and the effects of product mix, repair programs, and costs such as tariffs. These filings also describe the importance of Pro-Dex’s largest customer, shipments of next generation orthopedic handpieces, and repair revenue for legacy products, all of which are central to understanding the company’s revenue profile.
Users can also examine current reports on Form 8-K, where Pro-Dex discloses material events such as earnings announcements, contract developments, executive and director compensation decisions, equity incentive awards, and the results of its annual meeting of shareholders. For example, recent 8-K filings detail restricted share grants under the company’s equity incentive plan, discretionary cash bonuses for executives, and shareholder voting outcomes on director elections, auditor ratification, and amendments to the equity incentive plan.
In addition, the proxy statement filed on Form DEF 14A provides information on corporate governance, board composition, executive compensation, and proposals submitted to shareholders. Together, these documents offer a comprehensive view of Pro-Dex’s financial reporting, governance practices, and key risks and opportunities.
On Stock Titan, Pro-Dex filings are updated from EDGAR and accompanied by AI-powered summaries that highlight the main points of lengthy 10-Ks, 10-Qs, and 8-Ks, helping readers quickly understand what has changed. The platform also makes it easier to navigate to filings related to executive and director compensation, equity plans, and other matters that can influence shareholders’ evaluation of PDEX.
Pro-Dex, Inc. completed the acquisition of all membership interests of Advanced Precision Machining LLC on February 9, 2026 for approximately
To fund the cash portion, Pro-Dex entered into a Second Amended and Restated Credit and Security Agreement with UMB Bank and issued Term Note D in the principal amount of
Advanced Precision Machining manufactures machined components for multiple industries, including medical devices and aerospace, and has long supplied Pro-Dex sub-assemblies. Management describes the deal as part of expansion plans tied to a recently announced contract extension with its largest customer and expected revenue growth, while also aiming to maintain and expand Advanced Precision Machining’s business with other industries.
Pro-Dex, Inc. furnished an update on its recent financial results by announcing that it issued a press release covering its financial performance for the second quarter and six months ended December 31, 2025. The company attached this press release as Exhibit 99.1 to the current report.
The report clarifies that the press release and related information are being furnished rather than filed for liability purposes under securities laws. The filing also includes an exhibit for the cover page interactive data file and is signed on behalf of the company by its Chief Financial Officer, Alisha K. Charlton.
Pro-Dex, Inc. reported higher sales and profits for the three and six months ended December 31, 2025. Quarterly net sales rose to $18.7 million from $16.8 million, while net income increased to $2.2 million, or $0.66 diluted per share, up from $0.61.
For the six-month period, net sales grew to $37.2 million from $31.7 million and net income improved to $6.9 million, or $2.07 diluted per share, versus $1.33. Growth was driven mainly by orthopedic device sales tied to a next-generation handpiece for the company’s largest customer and stronger CMF driver demand, partially offset by lower repair revenue.
Pro-Dex realized $8.9 million of cash proceeds from the sale of Monogram Technologies shares and recorded a $6.8 million realized gain, contributing to stronger cash flow and lifting cash and cash equivalents to $8.0 million. Total notes payable fell to $10.5 million. Customer concentration remains high, with one customer representing about 79% of sales and 82% of accounts receivable, and order backlog was approximately $37.4 million.
Pro-Dex, Inc. director Angelita Domingo reported a small purchase of company stock through an employee plan. On 01/22/2026, she acquired 18 shares of common stock at a price of $34.36 per share in a transaction made under the company’s Employee Stock Purchase Plan, which is described as exempt under Rule 16b-3(c) and Rule 16b-3(d). After this transaction, she directly held 15,465 shares of Pro-Dex common stock.
PRO DEX INC (PDEX)11/21/2025. The filing shows the director acquired 900 shares of common stock at a price of $32.73 per share in a directly owned account, bringing the directly held total to 2,900 shares. On the same date, an additional 2,200 shares of common stock were acquired at $32.70 per share and are reported as indirectly owned by the director’s spouse, bringing the spouse’s reported indirect holdings to 16,896 shares. The filing is signed by an attorney-in-fact on behalf of the reporting person.
PRO DEX INC (PDEX)
The filing explains that these 72 shares were forfeited to pay payroll taxes related to the vesting of 200 restricted shares that were originally granted on 11/20/2024 under the company’s 2016 Equity Incentive Plan. This is a routine tax-withholding event tied to equity compensation rather than an open-market sale.
Pro-Dex, Inc. (PDEX) insider equity grant: Director and 10% owner Nicholas John Swenson received a grant of 1,000 shares of Pro-Dex common stock on 11/20/2025 at a stated price of $0.00 per share. These are restricted shares issued under the company’s 2016 Equity Incentive Plan and vest in equal installments over five years, conditioned on his continued service to Pro-Dex during the vesting period.
After this grant, he beneficially owns 97,613 shares directly and 926,730 shares indirectly through AO Partners I, LP. The filing is made as a Form 4 for a single reporting person.
Pro-Dex, Inc. (PDEX) director Katrina Marie Kramer Philp reported an equity grant from the company. On 11/20/2025 she received 1,000 shares of common stock as an award of restricted shares under Pro-Dex’s 2016 Equity Incentive Plan at a stated price of $0.00 per share. After this grant, she beneficially owns 2,000 common shares directly and 14,696 common shares indirectly through her spouse.
The restricted shares vest in equal installments over five years following the grant date, and vesting depends on her continued service to Pro-Dex during that period. The filing is made as a Form 4 for a single reporting person in her capacity as a director of the company.
Pro-Dex, Inc. (PDEX) director David C. Hovda reported receiving a grant of 1,000 shares of Pro-Dex common stock on 11/20/2025. The filing shows these shares were acquired at a stated price of $0, reflecting a restricted stock award rather than an open‑market purchase. Following this grant, Hovda beneficially owns 4,300 Pro-Dex shares in direct ownership.
The 1,000 restricted shares were granted under Pro-Dex’s 2016 Equity Incentive Plan. They vest in equal installments over five years after the grant date, as long as Hovda continues to provide service to Pro-Dex during the vesting period. This Form 4 simply records the equity compensation awarded to a board member and the resulting change in his share ownership.
Pro-Dex, Inc. (PDEX) director received a grant of 1,000 shares of common stock on 11/20/2025. The shares were granted at a price of $0.00 under the company’s 2016 Equity Incentive Plan as restricted stock.
These restricted shares vest in equal installments over the five years following the grant date, and vesting depends on the director’s continued service to Pro-Dex during this period. After this grant, the reporting person beneficially owns 2,000 shares directly and 5,100 shares indirectly through an IRA.